Table 1 Clinicopathological correlation with H3K18Ac, P300 and SIRT2 expression analyzed by immunohistochemistry
Clinical | H3K18Ac | (p) | SIRT2 | (p) | P300 | (p) | |
|---|---|---|---|---|---|---|---|
Extraprostatic Extension | No (46) | 0.371(0.316–0.434) | 0.0152(0.010–0.019) | 0.135(0.125–0.150) | |||
Yes (24) | 0.375(0.308–0.414) | 0.71 | 0.0132(0.011–0.017) | 0.17 | 0.145(0.125–0.162) | 0.09 | |
Seminal Vesicle Invasion | No (54) | 0.373(0.318–0.431) | 0.015(0.011–0.019) | 0.135(0.125–0.15) | |||
Yes (17) | 0.365(0.306–0.414) | 0.41 | 0.011(0.010–0.016) | 0.12 | 0.146(0.128–0.165) | 0.03 | |
Laterality | U/L (4) | 0.380(0.323–0.410) | 0.010(0.0085–0.013) | 0.125(0.118–0.136) | |||
B/L (67) | 0.371(0.31–0.422) | 0.92 | 0.015(0.011–0.018) | 0.16 | 0.137(0.125–0.153) | 0.20 | |
Margins | No (44) | 0.371(0.312–0.429) | 0.0157(0.011–0.019) | 0.139(0.126–0.158) | |||
Yes (26) | 0.373(0.306–0.414) | 0.79 | 0.012(0.010–0.017) | 0.07 | 0.132(0.125–0.147) | 0.46 | |
Clinical stage | II (42) | 0.371(0.316–0.439) | 0.015(0.010–0.019) | 0.134(0.125–0.150) | |||
III (12) | 0.358(0.308–0.401) | 0.013(0.010–0.017) | 0.137(0.126–0.153) | ||||
IV (16) | 0.396(0.311–0.414) | 0.64 | 0.016(0.010–0.018) | 0.58 | 0.146(0.126–0.163 | 0.13 | |
PSA level (ng/ml) | 0–5 (6) | 0.343(0.296–0.456) | 0.011(0.009–0.015) | 0.136(0.124–0.146) | |||
5–10 (35) | 0.372(0.313–0.414) | 0.015(0.012–0.018) | 0.133(0.124–0.152) | ||||
>10 (12) | 0.365(0.307–0.425) | 0.96 | 0.011(0.010–0.019) | 0.15 | 0.145(0.134–0.160) | 0.51 | |
Gleason score | |||||||
(3 + 3, 3 + 4) | Low/Int (35) | 0.371(0.321–0.441) | 0.015(0.012–0.019) | 0.128(0.121–0.142) | |||
(4 + 3,4 + 4, 4 + 5) | High (19) | 0.345(0.298–0.412) | 0.15 | 0.011(0.009–0.015) | 0.02 | 0.134(0.124–0.152) | 0.68 |